San Sebastián
San Sebastián
San Sebastián, Spain45 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 2 | 2026-10-07 | NCT07862946 | |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-07 | NCT06653153 | |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, peritoneal neoplasm | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05257408 | |
| A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | multifocal motor neuropathy | Active, not recruiting | Phase 3 | 2026-09-22 | NCT06742190 | |
| Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU | acute respiratory failure | Recruiting | Not applicable | 2026-09-21 | NCT06322719 | |
| Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer | Diabetes Complications, Diabetic Foot, Foot Ulcer, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, skin disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-09-18 | NCT06667752 | |
| Neurovascular Product Surveillance Registry | Aneurysm, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not stated | 2026-09-15 | NCT02988128 | |
| RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain | Back Pain, Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not stated | 2026-09-11 | NCT01719055 | |
| Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Active, not recruiting | Phase 3 | 2026-09-01 | NCT04526665 | |
| Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, Myotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic dystrophy type 1, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Enrolling by invitation | Phase 3 | 2026-08-19 | NCT07008469 | |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-19 | NCT05774951 | |
| Pediatric Expansion Study of the Sentio System | Ear Diseases, Hearing Loss, Conductive, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, hearing loss, mixed conductive-sensorineural, nervous system disorder, otorhinolaryngologic disease | Active, not recruiting | Not applicable | 2026-08-14 | NCT06976086 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-06 | NCT05232916 | |
| A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-04 | NCT03521154 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06486441 | |
| A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 3 | 2026-07-27 | NCT07038200 | |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-07-27 | NCT06095583 | |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients | splenic marginal zone lymphoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05735834 | |
| Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-20 | NCT03833154 | |
| A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-17 | NCT06746116 | |
| Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial | Arterial Occlusive Diseases, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-07-15 | NCT05599061 | |
| Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-14 | NCT02032823 | |
| CARAMEL Observational Study | Artificial Intelligence (Al); Cardiovascular (CV) Risk; Cardiovascular Disease Risk Factor; Menopause; Perimenopause; Women (Between 30 to 60 Years Old) | Recruiting | Not stated | 2026-07-10 | NCT07695376 | |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06558279 | |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-07-02 | NCT03330847 |